Rapid Point-of-Care Diagnostic for Early Detection of Dengue Infection

 描述（由申请人提供）：用于早期检测登革热感染的快速床旁诊断（Cross Life Technologies Inc.） 登革病毒（DENV）是世界上最危险和最重要的病原体之一，每年有2.3亿例登革病毒感染病例，主要发生在拉丁美洲和东南亚。这些蚊媒病毒在许多热带和亚热带国家引起周期性爆发性流行病。交叉生命技术公司的登革热诊断正在开发中，以早期发现登革热感染，使患者可以得到有效治疗。 在发热期早期和快速检测登革病毒（DENV）感染对于适当的患者管理和控制疾病至关重要。然而，目前用于早期检测登革热的方法涉及在实验室中使用RT-PCR仪器，这在登革热流行的地区可能无法获得，并且可能太慢。Cross Life Technologies（CLT）建议开发一种模板辅助快速检测（塔拉）诊断方法，用于检测人体血液中的登革热病毒。塔拉登革热诊断将在15分钟内在护理点（POC）的纸条上检测登革热，以便患者可以快速，低成本地治疗。将开发一种能够检测和鉴定登革病毒4种血清型的灵敏核酸POC诊断试纸条装置，以便于更准确地检测登革感染， 来改善公众健康。我们建议开发一种使用创新的RNA扩增化学的多重登革热诊断检测方法。这项创新技术将提供一种无酶、无PCR、无仪器、低成本、一次性、快速和灵敏的POC登革热诊断方法，直接来自全血样本。

 DESCRIPTION (provided by applicant): Rapid Point-of-Care Diagnostic for Early Detection of Dengue Infection Cross Life Technologies Inc. Dengue viruses (DENV) are one of the most dangerous and significant pathogens in the world, and there are 230 million cases of dengue virus infections per year, mostly in Latin America and Southeast Asia. These mosquito-borne viruses cause periodic explosive epidemics in many tropical and sub-tropical countries. Cross Life technologies' dengue diagnostic is being developed to detect dengue infection early so that patients can be treated effectively. Early and rapid detection of dengue virus (DENV) infection during the febrile period is crucial for proper patient management and containment of the disease. However, current methods for early detection of dengue involve the use of RT-PCR instruments in the laboratory, which may not be available in areas where dengue is endemic, and which may be too slow. Cross Life Technologies (CLT) proposes to develop a Template Assisted Rapid Assay (TARA) diagnostics for detection of dengue viruses in human blood. TARA dengue diagnostic will detect dengue in 15 minutes on a paper strip at the point-of-care (POC) so that patients can be treated rapidly and at low cost. A sensitive nucleic acid POC diagnostic paper dipstick device capable of detecting and identifying the 4 serotypes of dengue virus will be developed in order to facilitate more accurate detection of dengue infection in order to improve public health. We propose the development of a multiplex dengue diagnostic assay using an innovative RNA amplification chemistry. This innovative technology will provide an enzyme-free, PCR-less, instrumentation-free, low-cost, disposable, rapid and sensitive POC dengue diagnostics directly from whole blood samples.